Shaun Hussain
Neurology with Special Qualifications in Child Neurology · Los Angeles, CANPI 1902067796
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Greenwich Biosciences, Inc. at 51.6% of the total. Reporting peaked in 2019 at $16,623 and has fallen 96.5% since, to $588 in 2025. Among neurology with special qualifications in child neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $554.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Greenwich Biosciences, Inc.$21K
- Radius Health, Inc.$15K
- Jazz Pharmaceuticals Inc.$1K
- West Therapeutics Development, LLC$1K
- Aquestive Therapeutics, Inc.$553
- UCB, Inc.$517
- plus $1K from 9 others
Across 50 payments — averaging $6787.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$281K
- GW Research Limited$23K
- Zogenix Inc.$17K
- Eisai Inc.$17K
- UCB SA$2K
What the payments were for
- Consulting fees$17,80545%
- Speaking & faculty fees$18,22946%
- Travel & lodging$1,5944%
- Food & beverage$2,2856%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Greenwich Biosciences, Inc. | 29 | $20,601 |
| Radius Health, Inc. | 6 | $14,575 |
| Jazz Pharmaceuticals Inc. | 13 | $1,453 |
| West Therapeutics Development, LLC | 1 | $1,050 |
| Aquestive Therapeutics, Inc. | 3 | $553 |
| UCB, Inc. | 7 | $517 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $480 |
| Lundbeck LLC | 1 | $160 |
| Livanova USA, Inc. | 1 | $152 |
| SK Life Science, Inc. | 2 | $145 |
| Pyros Pharmaceuticals, Inc. | 1 | $114 |
| Neurelis, Inc. | 2 | $49 |
| Acadia Pharmaceuticals Inc | 1 | $37 |
| Immedica Pharma US, Inc. | 1 | $27 |
| Travere Therapeutics, Inc. | 3 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$21,507
- SYMPAZAN$500
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$152
- VIGPODER$114
How this compares
$39,920 in reported general payments places this provider in the 90th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Topiramate ErTopiramate | 12 | $5,599 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Los Angeles
- Rajsekar RajaramanLos Angeles$134K
- Deborah HolderLos Angeles$130K
- Leigh Maria Ramos PlattLos Angeles$59K
- Mohsen HamzaLos Angeles$24K
- Tena RosserLos Angeles$7K
- Arthur PartikianLos Angeles$7K
- Michael ChezSacramento$374K
- Allen BottOakland$372K
- Joseph SullivanSan Francisco$240K
- Ann SegerenStanford$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.